CD8A and neoplasm: The oncolytic Ad5/3-hTERT-E1A-hCD40L (CGTG-401) induced multiple antitumor effects including reduced tumor growth via apoptosis, increased number of cytotoxic CD8 T cells in the tumor, and upregulation of TH1 associated cytokines [115].